Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 8:2021:3619131.
doi: 10.1155/2021/3619131. eCollection 2021.

Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination

Josef Finsterer  1
Affiliations
Case Reports

Exacerbating Guillain-Barré Syndrome Eight Days after Vector-Based COVID-19 Vaccination

Josef Finsterer. Case Rep Infect Dis. .

Abstract

Since the introduction of mRNA technology-based and vector-based COVID-19 vaccines, adverse reactions to these agents have been occasionally reported. Exacerbation of Guillain-Barré syndrome (GBS) shortly after COVID-19 vaccination has not been communicated. The patient is a 32-year-old male who developed progressive sensory disturbances and muscle weakness 8 days after the first dosage of a vector-based vaccine. Cerebrospinal fluid investigations revealed a dissociation cyto-albuminque, and nerve conduction studies revealed demyelination. Intravenous immunoglobulin (IVIG) exhibited only a marginal effect for both sensory and motor deficits. The patient's history was moreover positive for previous GBS with marked motor deficits 14 years earlier, which responded favourably to IVIG leading to almost complete recovery within 9 months of rehabilitation. Although apparently extremely rare, neurologists should remain vigilant for a potential recurrence of GBS after vaccination with a vector-based COVID-19 vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Logunov D. Y., Dolzhikova I. V., Shcheblyakov D. V., et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397(10275):671–681. doi: 10.1016/s0140-6736(21)00234-8. - DOI - PMC - PubMed
    1. Klimek L., Chaker A. M., Cuevas M. Allergische Reaktionen auf COVID-19-Impfungen – was HNO-Ärzte wissen sollten–Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19, weitere Impfstoff-Kandidaten und assoziierte Immunphänomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe. Laryngorhinootologie. 2021;100(4):344–354. doi: 10.1055/a-1372-3270. - DOI - PubMed
    1. Mitchell O. R., Dave R., Bekker J., Brennan P. A. Supraclavicular lymphadenopathy following COVID-19 vaccination: an increasing presentation to the two-week wait neck lump clinic? British Journal of Oral and Maxillofacial Surgery. 2021;59(3):384–385. doi: 10.1016/j.bjoms.2021.02.002. - DOI - PMC - PubMed
    1. Soyfer V., Gutfeld O., Shamai S., Schlocker A., Merimsky O. COVID-19 vaccine induced radiation recall phenomenon. International Journal of Radiation Oncology, Biology, Physics. 2021 doi: 10.1016/j.ijrobp.2021.02.048. - DOI - PMC - PubMed
    1. Repajic M., Lai X. L., Xu P., Liu A. Bellʼs Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bellʼs palsy. Brain, Behavior, & Immunity-Health. 2021;13 doi: 10.1016/j.bbih.2021.100217.100217 - DOI - PMC - PubMed

Publication types

LinkOut - more resources